Contezolid and contezolid acefosamil
Next generation oral and IV oxazolidinone with improved safety to treat methicillin-resistant S. aureus (MRSA)
Reduced risk of myelosuppression was shown in both preclinical & clinical studies including a Phase3 registration study in complicated skin infections
- Antimicrobial compound/strategy
- Marketed product
- License, Co-develop, Joint Venture, Sell
Infectious disease area:
- North America
Contezolid (oral), contezolid acefosamil (intravenous) and MRX-8 (intravenous) are available for licensing and/or co-development outside of greater China.
Pharmaceutical development and commericalization company focused on antibiotics and rare diseases
Next generation intravenous polymyxin to treat multidrug-resistant Gram-negative infections with the potential for reduced nephtrotoxicity, while maintaining excellent efficacy.